{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T13:40:18Z","timestamp":1732887618029,"version":"3.30.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-024-06110-2","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T07:27:22Z","timestamp":1732778842000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chidamide and venetoclax synergistically regulate the Wnt\/\u03b2-catenin pathway by MYCN\/DKK3 in B-ALL"],"prefix":"10.1007","author":[{"given":"Linlin","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Desheng","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongyi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhibo","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JiaLi","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinghua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Emails","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"6110_CR1","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00018-017-2620-z","volume":"75","author":"C Malouf","year":"2018","unstructured":"Malouf C, Ottersbach K (2018) Molecular processes involved in B cell acute lymphoblastic leukaemia. Cell Mol Life Sci 75:417\u2013446. https:\/\/doi.org\/10.1007\/s00018-017-2620-z","journal-title":"Cell Mol Life Sci"},{"key":"6110_CR2","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1080\/10428194.2017.1335397","volume":"59","author":"A Kansagra","year":"2018","unstructured":"Kansagra A, Dahiya S, Litzow M (2018) Continuing challenges and current issues in acute lymphoblastic leukemia. Leuk Lymphoma 59:526\u2013541. https:\/\/doi.org\/10.1080\/10428194.2017.1335397","journal-title":"Leuk Lymphoma"},{"key":"6110_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-016-0519-8","volume":"18","author":"A Ronson","year":"2016","unstructured":"Ronson A, Tvito A, Rowe JM (2016) Treatment of relapsed\/refractory acute lymphoblastic leukemia in adults. Curr Oncol Rep 18:1\u201310. https:\/\/doi.org\/10.1007\/s11912-016-0519-8","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"6110_CR4","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/j.1365-2141.2007.06667.x","volume":"138","author":"NI Khan","year":"2007","unstructured":"Khan NI, Bradstock KF, Bendall LJ (2007) Activation of Wnt\/beta-catenin pathway mediates growth and survival in B-cell progenitor acute lymphoblastic leukaemia. Br J Haematol 138(3):338\u2013348. https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06667.x","journal-title":"Br J Haematol"},{"issue":"24","key":"6110_CR5","doi-asserted-by":"publisher","first-page":"6362","DOI":"10.1182\/blood-2011-04-350850","volume":"118","author":"A Kuhnl","year":"2011","unstructured":"Kuhnl A, Gokbuget N, Kaiser M, Schlee C, Stroux A, Burmeister T, Mochmann LH, Hoelzer D, Hofmann WK, Thiel E, Baldus CD (2011) Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia. Blood 118(24):6362\u20136367. https:\/\/doi.org\/10.1182\/blood-2011-04-350850","journal-title":"Blood"},{"issue":"3","key":"6110_CR6","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3390\/ijms21031098","volume":"21","author":"F Chiarini","year":"2020","unstructured":"Chiarini F, Paganelli F, Martelli AM, Evangelisti C (2020) The role played by Wnt\/\u03b2-catenin signaling pathway in acute lymphoblastic leukemia. Int J Mol Sci 21(3):1098. https:\/\/doi.org\/10.3390\/ijms21031098","journal-title":"Int J Mol Sci"},{"issue":"2","key":"6110_CR7","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/ijc.23913","volume":"124","author":"EJ Lee","year":"2010","unstructured":"Lee EJ, Jo M, Rho SB, Park K, Yoo YN, Park J, Chae M, Zhang W, Lee JH (2010) Dkk3, downregulated in cervical cancer, functions as a negative regulator of beta-catenin. Int J Cancer 124(2):287\u2013297. https:\/\/doi.org\/10.1002\/ijc.23913","journal-title":"Int J Cancer"},{"issue":"1","key":"6110_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ccell.2015.12.009","volume":"29","author":"H Mathsyaraja","year":"2016","unstructured":"Mathsyaraja H, Eisenman RN (2016) Parsing myc paralogs in Oncogenesis. Cancer Cell 29(1):1\u20132. https:\/\/doi.org\/10.1016\/j.ccell.2015.12.009","journal-title":"Cancer Cell"},{"issue":"10","key":"6110_CR9","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1200\/JCO.2008.17.9432","volume":"27","author":"S Pfister","year":"2009","unstructured":"Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, Wittmann A, Devens F, Gerber NU, Joos S, Kulozik A, Reifenberger G, Rutkowski S, Wiestler OD, Radlwimmer B, Scheurlen W, Lichter P, Korshunov A (2009) Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncology: Official J Am Soc Clin Oncol 27(10):1627\u20131636. https:\/\/doi.org\/10.1200\/JCO.2008.17.9432","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"1","key":"6110_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.canlet.2015.03.044","volume":"363","author":"L Evans","year":"2015","unstructured":"Evans L, Chen L, Milazzo G, Gherardi S, Perini G, Willmore E, Newell DR, Tweddle DA (2015) SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma. Cancer Lett 363(1):37\u201345. https:\/\/doi.org\/10.1016\/j.canlet.2015.03.044","journal-title":"Cancer Lett"},{"key":"6110_CR11","doi-asserted-by":"publisher","unstructured":"Charlet J, Szemes M, Malik KT, Brown KW (2014) MYCN is recruited to the RASSF1A promoter but is not critical for DNA hypermethylation in neuroblastoma, Molecular carcinogenesis. 53(5):413\u2013420. https:\/\/doi.org\/10.1002\/mc.21994","DOI":"10.1002\/mc.21994"},{"issue":"1","key":"6110_CR12","doi-asserted-by":"publisher","first-page":"120","DOI":"10.18632\/oncotarget.1337","volume":"5","author":"A Astolfi","year":"2014","unstructured":"Astolfi A, Vendemini F, Urbini M, Melchionda F, Masetti R, Franzoni M, Libri V, Serravalle S, Togni M, Paone G, Montemurro L, Bressanin D, Chiarini F, Martelli AM, Tonelli R, Pession A (2014) MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia. Oncotarget 5(1):120\u2013130. https:\/\/doi.org\/10.18632\/oncotarget.1337","journal-title":"Oncotarget"},{"key":"6110_CR13","doi-asserted-by":"publisher","unstructured":"Baylin SB, Jones PA (2016) Epigenetic determinants of Cancer, Cold Spring Harbor perspectives in biology 8 (9). a019505. https:\/\/doi.org\/10.1101\/cshperspect.a019505","DOI":"10.1101\/cshperspect.a019505"},{"key":"6110_CR14","doi-asserted-by":"publisher","unstructured":"Esteller M (2008) Epigenetics in cancer, the New England journal of medicine 358 (11). 1148\u20131159. https:\/\/doi.org\/10.1056\/NEJMra072067","DOI":"10.1056\/NEJMra072067"},{"issue":"1","key":"6110_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13148-020-00962-x","volume":"12","author":"P Zhang","year":"2020","unstructured":"Zhang P, Zhang M (2020) Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma. Clin Epigenetics 12(1):169. https:\/\/doi.org\/10.1186\/s13148-020-00962-x","journal-title":"Clin Epigenetics"},{"key":"6110_CR16","doi-asserted-by":"publisher","first-page":"116532","DOI":"10.1016\/j.ejmech.2024.116532","volume":"274","author":"S Ma","year":"2024","unstructured":"Ma S, Long G, Jiang Z, Zhang Y, Sun L, Pan Y, You Q, Guo X (2024) Recent advances in targeting histone H3 lysine 36 methyltransferases for cancer therapy. Eur J Med Chem 274:116532. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116532","journal-title":"Eur J Med Chem"},{"issue":"10","key":"6110_CR17","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nrc3130","volume":"11","author":"SB Baylin","year":"2011","unstructured":"Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 11(10):726\u2013734. https:\/\/doi.org\/10.1038\/nrc3130","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"6110_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.canlet.2011.11.036","volume":"318","author":"R Francisco","year":"2012","unstructured":"Francisco R, P\u00e9rez-Perarnau A, Cort\u00e9s C, Gil J, Tauler A, Ambrosio S (2012) Histone deacetylase inhibition induces apoptosis and autophagy in human neuroblastoma cells, cells. Cancer Lett 318(1):42\u201352. https:\/\/doi.org\/10.1016\/j.canlet.2011.11.036","journal-title":"Cancer Lett"},{"issue":"3","key":"6110_CR19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.5582\/irdr.2016.01024","volume":"5","author":"X Lu","year":"2016","unstructured":"Lu X, Ning Z, Li Z, Cao H, Wang X (2016) Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China. Intractable Rare Dis Res 5(3):185\u2013191. https:\/\/doi.org\/10.5582\/irdr.2016.01024","journal-title":"Intractable Rare Dis Res"},{"issue":"7","key":"6110_CR20","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1111\/jcmm.13644","volume":"22","author":"D Kong","year":"2018","unstructured":"Kong D, Zhao L, Sun L, Fan S, Li H, Zhao Y, Guo Z, Lin L, Cui L, Wang K, Chen W, Zhang Y, Zhou J, Li Y (2018) MYCN is a novel oncogenic target in adult B-ALL that activates the Wnt\/\u03b2-catenin pathway by suppressing DKK3. J Cell Mol Med 22(7):3627\u20133637. https:\/\/doi.org\/10.1111\/jcmm.13644","journal-title":"J Cell Mol Med"},{"key":"6110_CR21","doi-asserted-by":"publisher","unstructured":"Zhao L, Lv C, Sun L, Li Q, Wang Y, Wu M, Wang Y, Guo Z, Bian S, Kong D, Lin L (2021) Histone deacetylase inhibitor chidamide regulates the Wnt\/beta-catenin pathway by MYCN\/DKK3 in B-ALL, investigational new drugs. 39(4):961\u2013970. https:\/\/doi.org\/10.1007\/s10637-021-01079-5","DOI":"10.1007\/s10637-021-01079-5"},{"issue":"18","key":"6110_CR22","doi-asserted-by":"publisher","first-page":"10957","DOI":"10.3390\/ijms231810957","volume":"23","author":"S Aumann","year":"2022","unstructured":"Aumann S, Shaulov A, Haran A, Gross Even-Zohar N, Vainstein V, Nachmias B (2022) The emerging role of Venetoclax-based treatments in Acute Lymphoblastic Leukemia. Int J Mol Sci 23(18):10957. https:\/\/doi.org\/10.3390\/ijms231810957","journal-title":"Int J Mol Sci"},{"issue":"17","key":"6110_CR23","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1158\/1078-0432.CCR-14-0259","volume":"20","author":"S Suryani","year":"2014","unstructured":"Suryani S, Carol H, Chonghaile TN, Frismantas V, Sarmah C, High L, Bornhauser B, Cowley MJ, Szymanska B, Evans K (2014) Boehm, Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts. Clin cancer Research: Official J Am Association Cancer Res 20(17):4520\u20134531. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0259","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"11","key":"6110_CR24","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1182\/blood-2016-09-738070","volume":"129","author":"V Frismantas","year":"2017","unstructured":"Frismantas V, Dobay MP, Rinaldi A, Tchinda J, Dunn SH, Kunz J, Richter-Pechanska P, Marovca B, Pail O, Jenni S, Diaz-Flores E (2017) Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood 129(11):e26\u2013e37. https:\/\/doi.org\/10.1182\/blood-2016-09-738070","journal-title":"Blood"},{"issue":"25","key":"6110_CR25","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","volume":"124","author":"S Peirs","year":"2014","unstructured":"Peirs S, Matthijssens F, Goossens S, Van de Walle I, Ruggero K, De Bock CE, Degryse S, Cant\u00e9-Barrett K, Briot D, Clappier E, Lammens T (2014) ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood 124(25):3738\u20133747. https:\/\/doi.org\/10.1182\/blood-2014-05-574566","journal-title":"Blood"},{"issue":"4","key":"6110_CR26","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/leu.2008.1","volume":"22","author":"S Inoue","year":"2008","unstructured":"Inoue S, Walewska R, Dyer MJ, Cohen GM (2008) Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells. Leukemia 22(4):819\u2013825. https:\/\/doi.org\/10.1038\/leu.2008.1","journal-title":"Leukemia"},{"issue":"3","key":"6110_CR27","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1158\/0008-5472.CAN-15-1751","volume":"76","author":"CM Adams","year":"2016","unstructured":"Adams CM, Hiebert SW, Eischen CM (2016) Myc induces miRNA-Mediated apoptosis in response to HDAC inhibition in hematologic malignancies. Cancer Res 76(3):736\u2013748. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1751","journal-title":"Cancer Res"},{"issue":"9","key":"6110_CR28","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1038\/leu.2014.81","volume":"28","author":"SL Locatelli","year":"2014","unstructured":"Locatelli SL, Cleris L, Stirparo GG, Tartari S, Saba E, Pierdominici M, Malorni W, Carbone A, Anichini A, Carlo-Stella C (2014) BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts. Leukemia 28(9):1861\u20131871. https:\/\/doi.org\/10.1038\/leu.2014.81","journal-title":"Leukemia"},{"issue":"12","key":"6110_CR29","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1002\/kjm2.12283","volume":"36","author":"J Peng","year":"2022","unstructured":"Peng J, Li SJ, Fu X, Liu Y, Zhao XL (2022) Chidamide acts on the histone deacetylase-mediated miR-34a\/Bcl-2 axis to regulate NB4 cell line proliferation and apoptosis. Kaohsiung J Med Sci 36(12):1004\u20131013. https:\/\/doi.org\/10.1002\/kjm2.12283","journal-title":"Kaohsiung J Med Sci"},{"issue":"26","key":"6110_CR30","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.2174\/1381612827666210701152250","volume":"27","author":"S Liang","year":"2021","unstructured":"Liang S, Zhou X, Cai D, Rodrigues-Lima F, Wang L (2021) Chidamide inhibits cell proliferation via the PI3K\/AKT pathway in K562 cells based on Network Pharmacology and experimental validation. Curr Pharm Design 27(26):2990\u20132998. https:\/\/doi.org\/10.2174\/1381612827666210701152250","journal-title":"Curr Pharm Design"},{"issue":"9","key":"6110_CR31","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41419-020-02972-2","volume":"11","author":"K Chen","year":"2020","unstructured":"Chen K, Yang Q, Zha J, Deng M, Zhou Y, Fu G, Bi S, Feng L, Xu-Monette ZY, Chen XL, Fu G (2020) Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia. Cell Death Dis 11(9):778. https:\/\/doi.org\/10.1038\/s41419-020-02972-2","journal-title":"Cell Death Dis"},{"issue":"1","key":"6110_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-020-01792-8","volume":"39","author":"H Wang","year":"2020","unstructured":"Wang H, Liu YC, Zhu CY, Yan F, Wang MZ, Chen XS, Wang XK, Pang BX, Li YH, Liu DH, Gao CJ (2020) Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3-AKT-P21-CDK2 signaling pathway. J Experimental Clin cancer Res 39(1):1\u201319. https:\/\/doi.org\/10.1186\/s13046-020-01792-8","journal-title":"J Experimental Clin cancer Res"},{"key":"6110_CR33","doi-asserted-by":"publisher","unstructured":"Lin L, Que Y, Lu P, Li H, Xiao M, Zhu X, Li D (2020) Chidamide inhibits Acute myeloid leukemia cell proliferation by lncRNA VPS9D1-AS1 downregulation via MEK\/ERK Signaling Pathway, Frontiers in pharmacology. 11:569651. https:\/\/doi.org\/10.3389\/fphar.2020.569651","DOI":"10.3389\/fphar.2020.569651"},{"issue":"4","key":"6110_CR34","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1080\/10428194.2019.1691195","volume":"61","author":"W Guan","year":"2020","unstructured":"Guan W, Jing Y, Dou L, Wang M, Xiao Y, Yu L (2020) Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma\/leukemia. Leuk Lymphoma 61(4):855\u2013861. https:\/\/doi.org\/10.1080\/10428194.2019.1691195","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"6110_CR35","doi-asserted-by":"publisher","first-page":"936","DOI":"10.3892\/mmr.2019.10873","volume":"21","author":"Z Chi","year":"2020","unstructured":"Chi Z, Gao H, Liu H, Wu B, Zhang B, Gu M, Yang W (2020) Chidamide induces necroptosis via regulation of c\u2013FLIPL expression in Jurkat and HUT\u201378 cells. Mol Med Rep 21(2):936\u2013944. https:\/\/doi.org\/10.3892\/mmr.2019.10873","journal-title":"Mol Med Rep"},{"issue":"5","key":"6110_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/mmr.2021.11947","volume":"23","author":"H Zhang","year":"2021","unstructured":"Zhang H, Chi F, Qin K, Mu X, Wang L, Yang B, Wang Y, Bai M, Li Z, Su L, Yu B (2021) Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs\/STAT3\/Bcl\u20132 pathway. Mol Med Rep 23(5):1\u20139. https:\/\/doi.org\/10.3892\/mmr.2021.11947","journal-title":"Mol Med Rep"},{"issue":"5","key":"6110_CR37","doi-asserted-by":"publisher","first-page":"616","DOI":"10.21147\/j.issn.1000-9604.2021.05.08","volume":"33","author":"L Gui","year":"2021","unstructured":"Gui L, Cao J, Ji D, Zhang H, Fan Q, Zhu J, Song Y, Jiang S, Ning Z, Yu J, Shi Y (2021) Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma. Chin J Cancer Res 33(5):616\u2013626. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2021.05.08","journal-title":"Chin J Cancer Res"},{"issue":"12","key":"6110_CR38","first-page":"5631","volume":"9","author":"Z Liu","year":"2017","unstructured":"Liu Z, Chen J, Wang H, Ding K, Li Y, Burbano Jlvan, Sundararaj R, Gamage J, Audu V, Fu R (2017) Chidamide shows synergistic cytotoxicity with cytarabine via inducing G0\/G1 arrest and apoptosis in myelodysplastic syndromes. Am J Translational Res 9(12):5631\u20135642","journal-title":"Am J Translational Res"},{"issue":"1","key":"6110_CR39","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3892\/or.2014.3595","volume":"33","author":"B Zhao","year":"2015","unstructured":"Zhao B, He T (2015) Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax\/Bcl-2 and P21 in pancreatic cancer. Oncol Rep 33(1):304\u2013310. https:\/\/doi.org\/10.3892\/or.2014.3595","journal-title":"Oncol Rep"},{"issue":"10","key":"6110_CR40","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1182\/blood-2016-03-707414","volume":"128","author":"SL Khaw","year":"2016","unstructured":"Khaw SL, Suryani S, Evans K, Richmond J, Robbins A (2016) Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. Blood 128(10):1382\u20131395. https:\/\/doi.org\/10.1182\/blood-2016-03-707414","journal-title":"Blood"},{"issue":"1","key":"6110_CR41","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1182\/blood-2019-129988","volume":"134","author":"N Jain","year":"2019","unstructured":"Jain N et al (2019) A multicenter phase I study combining venetoclax with mini-hyper-CVD in older adults with untreated and relapsed\/refractory acute lymphoblastic leukemia. Blood 134(1):3867\u20133867. https:\/\/doi.org\/10.1182\/blood-2019-129988","journal-title":"Blood"},{"issue":"9","key":"6110_CR42","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1080\/10428194.2021.1897807","volume":"62","author":"S Arora","year":"2021","unstructured":"Arora S, Vachhani P, Bachiashvili K, Jamy O (2021) Venetoclax with chemotherapy in relapse\/refractory early T-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma 62(9):2292\u20132294. https:\/\/doi.org\/10.1080\/10428194.2021.1897807","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"6110_CR43","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.clml.2019.09.608","volume":"20","author":"G Richard-Carpentier","year":"2020","unstructured":"Richard-Carpentier G, Jabbour E, Short NJ, Rausch CR, Savoy JM, Bose P, Yilmaz M, Jain N, Borthakur G, Ohanian M, Alvarado Y (2020) Clinical experience with Venetoclax Combined with Chemotherapy for relapsed or refractory T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 20(4):212\u2013218. https:\/\/doi.org\/10.1016\/j.clml.2019.09.608","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"6110_CR44","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.cell.2012.05.012","volume":"149","author":"H Clevers","year":"2012","unstructured":"Clevers H, Nusse R (2012) Wnt\/\u03b2-catenin signaling and disease. Cell 149(6):1192\u20131205. https:\/\/doi.org\/10.1016\/j.cell.2012.05.012","journal-title":"Cell"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06110-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06110-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06110-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T09:14:25Z","timestamp":1732785265000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06110-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":44,"alternative-id":["6110"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06110-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"assertion":[{"value":"16 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocols used for animal studies were approved by the Laboratory Animal Ethics Committee of The Fourth Affiliated Hospital of Harbin Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}